Ajanta Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Ajanta Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹89Over the last 3 years, every ₹100 of reported profit came with ₹89 of operating cash.
Lower than 63% of Healthcare companies in India.
Self-Funding Ratio
3.0×Over the last 3 years its own operating cash covered its investment spending (capex) 3.0 times.
Higher than 80% of Healthcare companies in India.
Cash Locked Ratio
₹39For every ₹100 of sales, ₹39 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹38 tied up three years earlier.
More money tied up than 76% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹28Sales grew 46% in 3 years; of every extra ₹100 of sales, ₹28 became extra profit.
Higher than 75% of Healthcare companies in India.
Asset Productivity Ratio
+46% / +32%In 3 years sales changed by +46% while total assets changed by +32%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
2.5×Debt due within a year is covered 2.5 times by its yearly operating cash.
Higher than 62% of Healthcare companies in India.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Higher than 65% of Healthcare companies in India.
Tangible Assets Ratio
99%Of every ₹100 the company owns, ₹99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 65% of Healthcare companies in India.
Tangible Net Worth Ratio
99%Of every ₹100 of net worth, ₹99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 67% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Ajanta Pharma Limited owes ₹0.26 for every ₹1 it owns. Net profit rose 15% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
36.2Investors pay ₹36.2 for every ₹1 of Ajanta Pharma Limited's yearly profit, lower than 51% of Healthcare companies in India.
P/B ratio
9.06The share price is 9.06 times Ajanta Pharma Limited's book value per share, higher than 80% of Healthcare companies in India.
Market cap
₹41,035 CrThe total market value of all of Ajanta Pharma Limited's shares at today's price (share price × number of shares), larger than 86% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹4,527 CrWhat Ajanta Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹362.29Net worth divided by the number of shares. The share price of ₹3,284 is 9.1 times this, which is the P/B above.
Return on equity (ROE)
25.1%Ajanta Pharma Limited earned 25.1% on its shareholders' money over the last year, higher than 87% of Healthcare companies in India.
Owes vs Owns
0.26×Ajanta Pharma Limited owes ₹0.26 for every ₹1 it owns (low), lower than 71% of Healthcare companies in India.
Dividend yield
1.88%Ajanta Pharma Limited pays 1.88% of its share price as dividends a year, higher than 91% of dividend-paying Healthcare companies in India.
Revenue growth
+18%Revenue rose 18% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Profit growth
+15%Net profit rose 15% in the year to Mar 2026, and grew 22% a year on average over 3 years.
Profit margin
19.5%Ajanta Pharma Limited keeps ₹20 of every ₹100 of revenue as net profit.
Cash quality
0.5×Cash from Ajanta Pharma Limited's business was 0.5× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
82.3×Ajanta Pharma Limited's operating profit covered its interest costs 82.3 times in the year to Mar 2026.
Cash vs debt
Net cashAjanta Pharma Limited held ₹403 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Ajanta Pharma Limited's P/E ratio?
Investors pay ₹36.2 for every ₹1 of Ajanta Pharma Limited's yearly profit, lower than 51% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Ajanta Pharma Limited: ₹41,035 Cr ÷ ₹4,527 Cr (31 Mar 2026) = 9.1.
What is Ajanta Pharma Limited's return on equity?
Ajanta Pharma Limited earned 25.1% on its shareholders' money over the last year, higher than 87% of Healthcare companies in India.
How much does Ajanta Pharma Limited owe compared with what it owns?
Ajanta Pharma Limited owes ₹0.26 for every ₹1 it owns (low), lower than 71% of Healthcare companies in India.
Does Ajanta Pharma Limited pay a dividend?
Yes. Ajanta Pharma Limited pays 1.88% of its share price as dividends a year, higher than 91% of dividend-paying Healthcare companies in India.
Is Ajanta Pharma Limited's revenue growing?
Revenue rose 18% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.